Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 505.39% | 57.33% | 85.29% | 50.56% | 47.15% |
| Total Depreciation and Amortization | -0.18% | 0.24% | -0.12% | -0.03% | -50.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.94% | -290.99% | -819.35% | 38.85% | 125.41% |
| Change in Net Operating Assets | 41.90% | -54.59% | -332.24% | -68.27% | -148.24% |
| Cash from Operations | 447.59% | 14.88% | -0.07% | 40.57% | 23.34% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -12.11% | -- |
| Cash from Investing | -- | -- | -- | -12.11% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 7.60% | -- |
| Issuance of Common Stock | -47.64% | -- | -99.99% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.62% | -102.08% | 95.97% | 509.65% | -226.69% |
| Cash from Financing | -33.51% | -101.98% | -137.11% | 7,478.78% | 2,701.79% |
| Foreign Exchange rate Adjustments | 145.72% | -180.62% | 190.58% | 233.42% | -53.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 833.05% | -285.06% | -13.90% | 130.31% | 61.93% |